I can't think of any milestones, progress or anything that would trigger any revs. The recent pattern is decent earnings, a PR that sounds really exciting then a debacle on the call when analysts start asking questions and the price falls. Let's hope they do some better prep for the analyst Q&A, but doubtful. I only want to hear one thing, we are considering all options to improve shareholder value including a sale, well maybe a second thing, DJ is planning to retire and we are looking for a successor.
let's hope that's the case. At this price, it seems like the pipeline is valued at about $0, so unless they do, or say something stupid... I would like to know what execs have been doing for the past year to earn their high salaries and stock options rewards. I can't see any notable progress in human clinical trials for some time.
Here's the Q1 sales info from Roche. $102MM in sales for Kadcyla in Q1. Also on April 17 Roche announced the launch of Kadcyla in Japan.
HER2 franchise (Herceptin, Perjeta, Kadcyla) (+17%) for HER2-positive breast cancer and HER2-
positive metastatic (advanced) gastric cancer. Herceptin sales rose 3% overall, with 4% growth in the
United States, 2% in Europe and 23% in Japan. International markets were stable, impacted by some
phasing of sales in Mexico and political instability in Iraq, however growth remained strong in China
from patient access programmes; and in Brazil with sales to the public healthcare system. Uptake for
the subcutaneous formulation of Herceptin has been very positive since its approval in Europe in
2013 and it is now available in many markets, including Germany and the UK. Demand for recently
launched medicines Perjeta and Kadcyla was very strong in the first quarter. Perjeta (178 million
Swiss francs), a medicine which is combined with Herceptin, grew significantly in the United States
in both metastatic and pre-surgical breast cancer. Uptake in Europe was also very strong, especially
in Germany and the UK. Kadcyla (102 million Swiss francs) is a targeted cancer medicine that can
attach to HER2-positive cancer cells and deliver chemotherapy directly to them, resulting in a highly
potent treatment with fewer adverse side effects. There was good initial uptake in Europe for Kadcyla
(primarily Germany), as well as continued growth in the United States. Following approvals in Japan
and the EU in late 2013, reimbursement discussions are well underway in these markets.